MarketCap
Facebook
X
Telegram
Cue Biopharma EV/EBITDA Ratio | CUE
Annual EV/EBITDA Ratio Cue Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.704 | -1.06 | -1.21 | -1.57 | -7.01 | -7.19 | -9.25 | -2.12 | -11 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.704 | -11 | -4.56 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agios Pharmaceuticals
AGIO
|
-3.53 | $ 31.77 | 1.23 % | $ 1.84 B |  USA |
 |
Equillium
EQ
|
-3.87 | $ 1.45 | -3.33 % | $ 83.1 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
10.5 | $ 1.6 | -14.05 % | $ 91 M | USA |
 |
Abeona Therapeutics
ABEO
|
-2.69 | $ 2.46 | -3.35 % | $ 130 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
36 | $ 18.13 | 9.85 % | $ 3.05 B | USA |
 |
Atossa Therapeutics
ATOS
|
-0.367 | $ 2.21 | 3.76 % | $ 19 M | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
-22.4 | - | -7.31 % | $ 49 M | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
-6.28 | - | - | $ 1.77 B | USA |
 |
ADC Therapeutics SA
ADCT
|
-3.2 | $ 1.51 | -9.88 % | $ 192 M |  Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
5.42 | $ 33.57 | -0.62 % | $ 1.93 B | USA |
 |
Ardelyx
ARDX
|
-49.8 | $ 3.0 | 2.39 % | $ 723 M | USA |
 |
Akebia Therapeutics
AKBA
|
19.9 | $ 0.54 | 1.8 % | $ 139 M | USA |
 |
Alector
ALEC
|
-2.95 | $ 2.54 | 3.05 % | $ 262 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-1.27 | $ 1.11 | -13.62 % | $ 59.6 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
8.92 | $ 21.39 | 0.52 % | $ 6.7 B | USA |
 |
Phathom Pharmaceuticals
PHAT
|
-9.75 | $ 5.45 | 2.16 % | $ 397 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-22.4 | $ 3.8 | 2.15 % | $ 728 M |  Canada |
 |
Agenus
AGEN
|
-9.32 | $ 7.02 | -1.82 % | $ 209 M | USA |
 |
AbCellera Biologics
ABCL
|
-6.16 | $ 12.44 | -0.52 % | $ 3.72 B | Canada |
 |
Artelo Biosciences
ARTL
|
-0.327 | $ 2.14 | 2.01 % | $ 405 K | USA |
|
Immatics N.V.
IMTX
|
-2.14 | $ 6.42 | -0.23 % | $ 785 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
0.398 | $ 1.08 | -4.42 % | $ 341 K | USA |
 |
Aligos Therapeutics
ALGS
|
-0.949 | $ 2.59 | -34.43 % | $ 25.6 M | USA |
 |
Aclaris Therapeutics
ACRS
|
-5.56 | $ 4.13 | -2.5 % | $ 506 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-65.6 | $ 29.38 | -2.91 % | $ 4.46 B | USA |
 |
Cellectar Biosciences
CLRB
|
0.0286 | $ 1.24 | -3.15 % | $ 3.23 M | USA |
|
Larimar Therapeutics
LRMR
|
-2.05 | $ 2.68 | 5.93 % | $ 223 M | USA |
 |
Biofrontera AG
BFRA
|
-98.1 | - | -8.24 % | $ 105 M | Germany |
 |
Pliant Therapeutics
PLRX
|
-0.518 | $ 0.78 | -2.19 % | $ 47.9 M | USA |
 |
Pharming Group N.V.
PHAR
|
118 | $ 13.02 | -1.06 % | $ 8.97 B |  Niderland |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
-1.55 | - | -6.97 % | $ 657 M | USA |
 |
Capricor Therapeutics
CAPR
|
-11.4 | $ 8.91 | -9.54 % | $ 414 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
11.2 | $ 29.06 | -1.09 % | $ 1.36 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
17.4 | - | 1.68 % | $ 4.65 B |  China |
 |
Aquestive Therapeutics
AQST
|
-7.66 | $ 3.52 | -0.56 % | $ 376 M | USA |
 |
Jaguar Health
JAGX
|
-1.3 | $ 0.44 | -0.21 % | $ 1.03 M | USA |
 |
Arvinas
ARVN
|
-8.74 | $ 6.9 | 2.07 % | $ 489 M | USA |
 |
Cerus Corporation
CERS
|
-87.2 | $ 1.95 | -6.04 % | $ 372 M | USA |
 |
Beam Therapeutics
BEAM
|
-8.71 | $ 25.16 | -6.88 % | $ 2.49 B | USA |
 |
Pulmatrix
PULM
|
-3.93 K | $ 1.39 | 2.58 % | $ 5.08 B | USA |
 |
Fortress Biotech
FBIO
|
-1.74 | $ 1.9 | -4.52 % | $ 53 M | USA |
 |
Inhibrx
INBX
|
-7.95 | $ 90.63 | -1.21 % | $ 4.27 B | USA |
 |
Entera Bio Ltd.
ENTX
|
-7.43 | $ 3.24 | -0.31 % | $ 150 M |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
-7.1 | - | - | $ 459 M | USA |
 |
Legend Biotech Corporation
LEGN
|
-49.4 | $ 20.25 | -16.63 % | $ 7.46 B | USA |
 |
CytomX Therapeutics
CTMX
|
-45.9 | $ 2.0 | 0.76 % | $ 276 M | USA |
 |
Krystal Biotech
KRYS
|
48.4 | $ 306.47 | 1.13 % | $ 8.87 B | USA |
 |
Kura Oncology
KURA
|
-3.8 | $ 7.56 | -0.13 % | $ 663 M | USA |
 |
Inhibikase Therapeutics
IKT
|
0.198 | $ 1.58 | -6.25 % | $ 155 M | USA |